Prescription-only medicine

Editorially reviewed · Last updated March 2026 · How we review

Part of Weight Loss Drug Comparison Index.

Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection

Orforglipron and Zepbound are both Eli Lilly weight loss drugs, but they work differently and deliver different results. Orforglipron is a once-daily oral pill — a non-peptide, small-molecule GLP-1 receptor agonist. Zepbound (tirzepatide) is a once-weekly injection — a dual GLP-1/GIP receptor agonist already FDA-approved for chronic weight management.

The core trade-off: Zepbound produces roughly twice the weight loss (-22.5% vs -12.4% in Phase 3 trials), but orforglipron removes the injection barrier entirely. No needles, no refrigeration, no injection site reactions. Lilly is positioning these as complementary options — orforglipron for accessibility and convenience, Zepbound for maximum proven efficacy.

Side-by-Side Comparison

	Orforglipron	Zepbound (Tirzepatide)
Developer	Eli Lilly	Eli Lilly
Delivery	Once-daily oral pill	Once-weekly injection (pen or vial)
Molecule type	Non-peptide small molecule	Peptide
Receptors	GLP-1 only (single agonist)	GLP-1 + GIP (dual agonist)
Max weight loss	-12.4% at 72 weeks (ATTAIN-1)	-22.5% at 72 weeks (SURMOUNT-1)
Max dose	36 mg daily	15 mg weekly
Food restrictions	None	None (injectable)
FDA status	Filed, decision expected Q2 2026	Approved (November 2023)
Self-pay cost	Expected $149-$399/month (LillyDirect)	$299-$449/month (LillyDirect vials)
Key advantage	No injections, daily pill, potentially lower cost	Nearly 2x the weight loss, proven track record

How They Work Differently

Orforglipron: Oral Small Molecule, One Receptor

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. This distinction matters. Every injectable GLP-1 drug on the market — semaglutide, tirzepatide, liraglutide — is a peptide that would be destroyed by stomach acid if swallowed. Orforglipron is a small molecule that survives the GI tract intact.

It activates only the GLP-1 receptor, which drives appetite suppression, insulin secretion, and slowed gastric emptying. Orforglipron exhibits biased agonism, favoring the G-protein signaling pathway (therapeutic effects) over beta-arrestin recruitment (receptor downregulation), which may reduce receptor desensitization over time.

The result: a pill you can take daily with no fasting requirements and no food restrictions — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting with plain water only.

Zepbound: Injectable Dual Agonist, Two Receptors

Zepbound (tirzepatide) activates both GLP-1 and GIP receptors simultaneously. The GLP-1 component suppresses appetite and controls blood glucose. The GIP (glucose-dependent insulinotropic polypeptide) component adds insulin sensitivity benefits and appears to amplify weight loss beyond what GLP-1 alone achieves.

This dual mechanism is why Zepbound produces roughly 22% weight loss at the highest dose — well beyond the 12-17% range typical of GLP-1-only drugs. Zepbound was the first obesity drug to demonstrate over 20% average weight loss in a Phase 3 trial (SURMOUNT-1).

Zepbound is administered as a once-weekly subcutaneous injection using a pre-filled pen or single-dose vial. The pens do not require refrigeration after first use and the injection process takes about 10 seconds.

Weight Loss Comparison

Phase 3 Trial Results

Drug	Trial	Duration	Max Weight Loss	Participants
Orforglipron 36 mg	ATTAIN-1 (Phase 3)	72 weeks	-12.4%	1,686
Orforglipron 12 mg	ATTAIN-1 (Phase 3)	72 weeks	-9.4%	1,686
Zepbound 15 mg	SURMOUNT-1 (Phase 3)	72 weeks	-22.5%	2,539
Zepbound 10 mg	SURMOUNT-1 (Phase 3)	72 weeks	-21.4%	2,539
Zepbound 5 mg	SURMOUNT-1 (Phase 3)	72 weeks	-16.0%	2,539

Even Zepbound's lowest dose (5 mg) produced more weight loss than orforglipron's highest dose (36 mg). The gap is consistent — Zepbound's dual receptor mechanism drives substantially more weight reduction across all dose levels.

Weight Loss Thresholds

Threshold	Orforglipron 36 mg (ATTAIN-1)	Zepbound 15 mg (SURMOUNT-1)
Lost at least 5%	79.0%	91%
Lost at least 10%	54.6%	81%
Lost at least 15%	36.0%	62%
Lost at least 20%	18.4%	40%

Important Caveats

These results come from different trials with different patient populations. ATTAIN-1 enrolled 1,686 adults with obesity or overweight (BMI 27+). SURMOUNT-1 enrolled 2,539 adults with obesity (BMI 30+) or overweight with comorbidities. Baseline characteristics differed, so this is a cross-trial comparison rather than a head-to-head result.

Side Effects Comparison

	Orforglipron 36 mg (ATTAIN-1)	Zepbound 15 mg (SURMOUNT-1)
Nausea	33.7%	33%
Diarrhea	23.1%	21%
Vomiting	24.0%	10%
Constipation	25.4%	11%
Severity	Mostly mild-moderate	Mostly mild-moderate
Discontinuation (adverse events)	10.3%	4.3-7.1%
Injection site reactions	N/A (oral)	Present

Both drugs share the standard GLP-1 gastrointestinal side effect profile — nausea, diarrhea, vomiting, and constipation are most common during the initial dose titration period and tend to improve over time.

Orforglipron has notably higher rates of vomiting (24.0% vs 10%) and constipation (25.4% vs 11%) compared to Zepbound. This may relate to daily oral dosing producing more consistent GI exposure versus Zepbound's weekly peaks. However, nausea rates are essentially identical between the two.

Zepbound can cause injection site reactions (redness, itching, or swelling at the injection site), which orforglipron avoids entirely as an oral pill. No safety signals for pancreatitis, retinal detachment, or ischemic optic neuropathy were found in orforglipron's Phase 3 data.

Cost and Access

Current and Expected Pricing

	Orforglipron (Expected)	Zepbound (Current)
Self-pay (LillyDirect)	$149-$399/month	$299-$449/month (vials)
Medicare	$50/month (if approved)	Not covered for obesity
List price	Not yet announced	~$1,060/month
Manufacturing	Small molecule (cheaper to produce)	Peptide (more expensive to produce)
Cold chain	No refrigeration needed	Vials: no refrigeration; Pens: refrigerate until first use

Orforglipron has a significant cost advantage built into its chemistry. Small molecules are cheaper to manufacture than injectable peptides — they do not require the complex biological synthesis processes that peptide drugs demand. Eli Lilly has signaled this in their projected pricing: the lowest orforglipron dose starts at $149/month through LillyDirect, compared to $299/month for Zepbound's starting dose.

The most notable pricing development: Lilly and the US government reached an agreement for $50/month Medicare access to orforglipron if approved. For context, Medicare currently does not cover Zepbound for obesity treatment, and the Treat and Reduce Obesity Act has not yet passed Congress.

Access Differences

Zepbound is available now. It has been FDA-approved since November 2023 and can be prescribed through any physician.
Orforglipron is not yet available. The FDA is reviewing the New Drug Application, with a decision expected in Q2 2026. It received the FDA Commissioner's National Priority Review Voucher, which could shorten the timeline.

Convenience vs Efficacy: The Core Decision

The Case for Orforglipron

No needles — a daily pill taken at any time of day
No food restrictions — unlike oral semaglutide, no fasting required
No refrigeration — shelf-stable small molecule
Lower cost — expected $149-$399/month vs $299-$449/month for Zepbound
Lower barrier to starting — many patients avoid injectables due to needle phobia
Medicare pricing deal — $50/month if approved, while Zepbound is not covered for obesity

The Case for Zepbound

Nearly 2x the weight loss — 22.5% vs 12.4%
Once-weekly dosing — one injection per week vs a daily pill
Available now — FDA-approved and prescribable today
Better responder rates — 62% lost 15%+ body weight vs 36% on orforglipron
Cardiovascular outcomes data — the SURPASS-CVOT trial showed a 10% reduction in major adverse cardiovascular events
Proven real-world track record — millions of patients treated since 2022

Who Might Choose Which?

Orforglipron first-line: Patients who refuse or cannot tolerate injections, those with moderate obesity who need 10-12% weight loss, cost-sensitive patients, Medicare beneficiaries
Zepbound first-line: Patients with severe obesity who need more than 15% weight loss, those comfortable with weekly injections, patients who want a proven FDA-approved drug available now
Step-up approach: Start with orforglipron for convenience, then switch to Zepbound if greater weight loss is needed
Step-down approach: Achieve target weight on Zepbound, then transition to orforglipron for long-term oral maintenance

Switching Between the Two

Lilly's ATTAIN-MAINTAIN trial studied what happens when patients switch from injectable incretins (including tirzepatide) to oral orforglipron. Patients switching from tirzepatide to orforglipron maintained most of their prior weight loss, with an average difference of only 5.0 kg (about 11 lbs) over 52 weeks.

This supports a practical clinical pathway: use Zepbound to achieve significant weight loss during the active treatment phase, then transition to orforglipron for long-term maintenance if the patient prefers an oral option. The 5 kg gap indicates some weight regain is expected when stepping down from a dual agonist to a single agonist, but the majority of weight loss is preserved.

Where Retatrutide Fits

For context, Lilly's investigational triple agonist retatrutide exceeds both orforglipron and Zepbound:

Drug	Receptors	Max Weight Loss	Trial
Orforglipron 36 mg	GLP-1	-12.4% (72 wks)	ATTAIN-1
Zepbound 15 mg	GLP-1 + GIP	-22.5% (72 wks)	SURMOUNT-1
Retatrutide 12 mg	GLP-1 + GIP + Glucagon	-28.7% (68 wks)	TRIUMPH-4

The pattern holds: more receptor targets correlate with greater weight loss. Retatrutide's glucagon receptor component adds energy expenditure on top of appetite suppression, pushing weight loss beyond what even Zepbound's dual agonist mechanism achieves. Lilly's head-to-head trial of retatrutide vs tirzepatide (TRIUMPH-5, active not recruiting) has primary completion in December 2026, with results expected to follow in 2027.

For detailed comparisons, see Retatrutide vs Tirzepatide and Retatrutide vs Orforglipron.

Frequently Asked Questions

Is orforglipron as effective as Zepbound for weight loss?

No. Zepbound produces nearly twice the weight loss (-22.5%) compared to orforglipron (-12.4%) in Phase 3 trials. Zepbound's dual receptor mechanism (GLP-1 + GIP) drives substantially more weight reduction than orforglipron's single GLP-1 receptor. The trade-off is that orforglipron is an oral pill while Zepbound requires weekly injections.

Is orforglipron cheaper than Zepbound?

Expected to be, yes. Orforglipron is projected to cost $149-$399/month through LillyDirect, compared to $299-$449/month for Zepbound vials. Small molecules are cheaper to manufacture than injectable peptides. Additionally, Lilly has agreed to a $50/month price for Medicare beneficiaries if orforglipron is approved, while Zepbound is not currently covered by Medicare for obesity.

Are orforglipron and Zepbound made by the same company?

Yes. Both are made by Eli Lilly. Orforglipron is Lilly's oral GLP-1 pill (filed for FDA approval, decision expected Q2 2026). Zepbound is Lilly's approved injectable dual agonist for obesity. Lilly is also developing retatrutide, a triple agonist injectable that exceeds both in weight loss.

Can I switch from Zepbound to orforglipron?

Early data supports this. The ATTAIN-MAINTAIN trial showed that patients switching from tirzepatide (Zepbound's active ingredient) to orforglipron maintained most of their weight loss, with an average difference of 5.0 kg over 52 weeks. This suggests orforglipron could work as a long-term oral maintenance option after achieving weight loss on Zepbound.

When will orforglipron be available?

Eli Lilly has filed orforglipron for FDA approval in over 40 countries. The US FDA decision for the obesity indication is expected in Q2 2026. It received the FDA Commissioner's National Priority Review Voucher, which could shorten the review timeline. If approved, Lilly has indicated it will be available through LillyDirect starting at $149/month.

Should I wait for orforglipron or start Zepbound now?

This depends on your individual circumstances. If you have significant weight to lose and are comfortable with injections, Zepbound is available now and produces greater weight loss. If you strongly prefer a pill, the orforglipron FDA decision is expected in Q2 2026. You could also start Zepbound now and potentially switch to orforglipron later for oral maintenance. Discuss options with your healthcare provider.

What are the side effects of orforglipron compared to Zepbound?

Both drugs cause similar gastrointestinal side effects: nausea, diarrhea, vomiting, and constipation. Orforglipron has higher vomiting (24.0% vs 10%) and constipation (25.4% vs 11%) rates. Nausea rates are comparable (~33% for both). Zepbound can cause injection site reactions, which orforglipron avoids as a pill. Both drugs see GI side effects improve after the initial dose escalation period.

Sources

Wharton S, et al. "Orforglipron in adults with obesity (ATTAIN-1)." New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2511774
Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038
Eli Lilly. "ATTAIN-MAINTAIN results: Orforglipron maintained weight loss after switching from injectables." Press Release
Eli Lilly. "Lilly lowers the price of Zepbound single-dose vials." Press Release
Eli Lilly. "What to know about orforglipron oral GLP-1." Lilly.com

This article is for informational purposes only and does not constitute medical advice. Orforglipron is an investigational compound that has not been approved by the FDA. Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Always consult a healthcare provider before starting any medication. This site is not affiliated with Eli Lilly or any pharmaceutical manufacturer.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources